Ocular Posterior Segment Distribution and Pharmacokinetics of Brimonidine After Intravitreal Administration in Guinea Pigs

J Ocul Pharmacol Ther. 2023 Sep;39(7):456-462. doi: 10.1089/jop.2023.0020. Epub 2023 Jun 13.

Abstract

Purpose: Brimonidine is a highly alpha-2 adrenergic agonist, which provides a potential myopia control effect. This study aimed to examine the pharmacokinetics and concentration of brimonidine in the posterior segment tissue of eyes in guinea pigs. Methods: A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was successfully used for brimonidine pharmacokinetics and tissue distribution research in guinea pigs following intravitreal administration (20 μg/eye). Results: Brimonidine concentrations in the retina and sclera were maintained at a high level (>60 ng/g) at 96 h postdosing. Brimonidine concentration peaked in the retina (377.86 ng/g) at 2.41 h and sclera (306.18 ng/g) at 6.98 h. The area under curve (AUC0-∞) was 27,179.99 ng h/g in the retina and 39,529.03 ng h/g in the sclera. The elimination half-life (T1/2e) was 62.43 h in the retina and 67.94 h in the sclera. Conclusions: The results indicated that brimonidine was rapidly absorbed and diffused to the retina and sclera. Meanwhile, it maintained higher posterior tissue concentrations, which can effectively activate the alpha-2 adrenergic receptor. This may provide pharmacokinetic evidence for the inhibition of myopia progression by brimonidine in animal experiments.

Keywords: LC-MS/MS; brimonidine; intravitreal administration; pharmacokinetics; tissue distribution.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brimonidine Tartrate
  • Chromatography, Liquid
  • Guinea Pigs
  • Myopia*
  • Tandem Mass Spectrometry / methods
  • Vitreous Body*

Substances

  • Brimonidine Tartrate